Crucible Therapeutics, a biopharmaceutical company developing novel therapies for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases, has appointed Dr Cliff Holloway as its Chief Executive Officer and a member of its Board of Directors.
Dr Holloway is an experienced biotechnology executive with over two decades of leadership in the sector. He has specialised in facilitating the growth, organisation, and culture of companies transitioning from the laboratory to the clinic by guiding teams through major clinical, regulatory, and development milestones.
Commenting on his appointment, Dr Holloway said:
“I’m thrilled to have the opportunity to lead Crucible and advance our programs towards delivering transformative therapies for patients with serious neurodegenerative diseases. I have a very personal mission to ensure Crucible’s success following the ALS diagnosis and passing of a very good friend and colleague just last year. Crucible’s novel RNA therapeutics represents an innovative approach to treating these devastating conditions and offers these patients much more than just hope. I look forward to working with our talented team and our world-class partners at the Sheffield Institute for Translational Neuroscience to drive our programs forward into the clinic and beyond.”
Crucible Therapeutics is a University of Sheffield spinout that launched in 2023 with seed financing from Northern Gritstone and Argobio Studios and operational support from Argobio Studios. The company is based on the world-class science of Co-founders Professor Guillaume Hautbergue, Professor Dame Pamela Shaw and Professor Mimoun Azzouz at the Sheffield Institute for Translational Neuroscience (SITraN) and the Sheffield National Institute for Health and Care Research Biomedical Research Centre (Sheffield NIHR BRC).